Risk factors for severe diarrhea with an afatinib treatment of non-small cell lung cancer:  A pooled analysis of clinical trials

Ashley M. Hopkins; Anh Minh Nguyen; C. S. Karapetis; Andrew Rowland; Michael Joseph Sorich

doi:10.3390/cancers10100384

Risk factors for severe diarrhea with an afatinib treatment of non-small cell lung cancer: A pooled analysis of clinical trials

Ashley M. Hopkins, Anh Minh Nguyen, C. S. Karapetis, Andrew Rowland, Michael Joseph Sorich

College of Medicine and Public Health

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

26 Downloads (Pure)

Abstract

Afatinib is an effective therapy for metastatic non-small cell lung cancer (NSCLC) but it is associated with a relatively high incidence of severe diarrhea. The association between pre-treatment candidate predictors (age, sex, race, performance status, renal function, hemoglobin, and measures of body mass) and severe (grade ≥ 3) diarrhea was evaluated using logistic regression with pooled individual participant data from seven clinical studies. A risk score was developed based on the count of major risk factors. Overall, 184 of 1151 participants (16%) experienced severe diarrhea with use of afatinib. Body weight, body mass index, and body surface area all exhibited a prominent non-linear association where risk increased markedly at the lower range (p < 0.005). Low weight (<45 kg), female sex, and older age (≥60 years) were identified as major independent risk factors (p < 0.01). Each risk factor was associated with a two-fold increase in the odds of severe diarrhea, and this was consistent between individuals commenced on 40 mg or 50 mg afatinib. A simple risk score based on the count of these risk factors identifies individuals at lowest and highest risk (C-statistic of 0.65). Risk of severe diarrhea for individuals commenced on 40 mg afatinib ranged from 6% for individuals with no risk factors to 33% for individuals with all three risk factors.

Original language	English
Article number	384
Number of pages	10
Journal	Cancers
Volume	10
Issue number	10
DOIs	https://doi.org/10.3390/cancers10100384
Publication status	Published - 15 Oct 2018

Bibliographical note

(CC-BY 4.0) Open Access article licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license (http://creativecommons.org/licenses/by/4.0).

Keywords

EGFR inhibitor
diarrhea
toxicity
prediction model
adverse event
Afatinib
Toxicity
Prediction model
Adverse event
Diarrhea

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers10100384Licence: CC BY

published versionFinal published version, 505 KBLicence: CC BY

Cite this

@article{e6791cd753954a21a42b7726b112e28a,

title = "Risk factors for severe diarrhea with an afatinib treatment of non-small cell lung cancer: A pooled analysis of clinical trials",

abstract = "Afatinib is an effective therapy for metastatic non-small cell lung cancer (NSCLC) but it is associated with a relatively high incidence of severe diarrhea. The association between pre-treatment candidate predictors (age, sex, race, performance status, renal function, hemoglobin, and measures of body mass) and severe (grade ≥ 3) diarrhea was evaluated using logistic regression with pooled individual participant data from seven clinical studies. A risk score was developed based on the count of major risk factors. Overall, 184 of 1151 participants (16%) experienced severe diarrhea with use of afatinib. Body weight, body mass index, and body surface area all exhibited a prominent non-linear association where risk increased markedly at the lower range (p < 0.005). Low weight (<45 kg), female sex, and older age (≥60 years) were identified as major independent risk factors (p < 0.01). Each risk factor was associated with a two-fold increase in the odds of severe diarrhea, and this was consistent between individuals commenced on 40 mg or 50 mg afatinib. A simple risk score based on the count of these risk factors identifies individuals at lowest and highest risk (C-statistic of 0.65). Risk of severe diarrhea for individuals commenced on 40 mg afatinib ranged from 6% for individuals with no risk factors to 33% for individuals with all three risk factors.",

keywords = "EGFR inhibitor, diarrhea, toxicity, prediction model, adverse event, Afatinib, Toxicity, Prediction model, Adverse event, Diarrhea",

author = "Hopkins, {Ashley M.} and Nguyen, {Anh Minh} and Karapetis, {C. S.} and Andrew Rowland and Sorich, {Michael Joseph}",

note = "(CC-BY 4.0) Open Access article licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license (http://creativecommons.org/licenses/by/4.0). ",

year = "2018",

month = oct,

day = "15",

doi = "10.3390/cancers10100384",

language = "English",

volume = "10",

journal = "Cancers",

issn = "2072-6694",

publisher = "MDPI",

number = "10",

}

TY - JOUR

T1 - Risk factors for severe diarrhea with an afatinib treatment of non-small cell lung cancer

T2 - A pooled analysis of clinical trials

AU - Hopkins, Ashley M.

AU - Nguyen, Anh Minh

AU - Karapetis, C. S.

AU - Rowland, Andrew

AU - Sorich, Michael Joseph

N1 - (CC-BY 4.0) Open Access article licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license (http://creativecommons.org/licenses/by/4.0).

PY - 2018/10/15

Y1 - 2018/10/15

N2 - Afatinib is an effective therapy for metastatic non-small cell lung cancer (NSCLC) but it is associated with a relatively high incidence of severe diarrhea. The association between pre-treatment candidate predictors (age, sex, race, performance status, renal function, hemoglobin, and measures of body mass) and severe (grade ≥ 3) diarrhea was evaluated using logistic regression with pooled individual participant data from seven clinical studies. A risk score was developed based on the count of major risk factors. Overall, 184 of 1151 participants (16%) experienced severe diarrhea with use of afatinib. Body weight, body mass index, and body surface area all exhibited a prominent non-linear association where risk increased markedly at the lower range (p < 0.005). Low weight (<45 kg), female sex, and older age (≥60 years) were identified as major independent risk factors (p < 0.01). Each risk factor was associated with a two-fold increase in the odds of severe diarrhea, and this was consistent between individuals commenced on 40 mg or 50 mg afatinib. A simple risk score based on the count of these risk factors identifies individuals at lowest and highest risk (C-statistic of 0.65). Risk of severe diarrhea for individuals commenced on 40 mg afatinib ranged from 6% for individuals with no risk factors to 33% for individuals with all three risk factors.

AB - Afatinib is an effective therapy for metastatic non-small cell lung cancer (NSCLC) but it is associated with a relatively high incidence of severe diarrhea. The association between pre-treatment candidate predictors (age, sex, race, performance status, renal function, hemoglobin, and measures of body mass) and severe (grade ≥ 3) diarrhea was evaluated using logistic regression with pooled individual participant data from seven clinical studies. A risk score was developed based on the count of major risk factors. Overall, 184 of 1151 participants (16%) experienced severe diarrhea with use of afatinib. Body weight, body mass index, and body surface area all exhibited a prominent non-linear association where risk increased markedly at the lower range (p < 0.005). Low weight (<45 kg), female sex, and older age (≥60 years) were identified as major independent risk factors (p < 0.01). Each risk factor was associated with a two-fold increase in the odds of severe diarrhea, and this was consistent between individuals commenced on 40 mg or 50 mg afatinib. A simple risk score based on the count of these risk factors identifies individuals at lowest and highest risk (C-statistic of 0.65). Risk of severe diarrhea for individuals commenced on 40 mg afatinib ranged from 6% for individuals with no risk factors to 33% for individuals with all three risk factors.

KW - EGFR inhibitor

KW - diarrhea

KW - toxicity

KW - prediction model

KW - adverse event

KW - Afatinib

KW - Toxicity

KW - Prediction model

KW - Adverse event

KW - Diarrhea

UR - http://www.scopus.com/inward/record.url?scp=85055522247&partnerID=8YFLogxK

U2 - 10.3390/cancers10100384

DO - 10.3390/cancers10100384

M3 - Article

SN - 2072-6694

VL - 10

JO - Cancers

JF - Cancers

IS - 10

M1 - 384

ER -